A Phase 2 interventional study of Active Placebo Dose MDMA-assisted therapy (25 mg) and Full Dose MDMA-assisted therapy (125 mg) in Posttraumatic Stress Disorder (PTSD), sponsored by Lykos Therapeutics. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 28th largest by enrollment, is one of 2 that started in 2013, is one of 28 in phase 2, and was the 6th registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 2, and was the 6th registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
The main question it aims to answer is: Is there a reduction in PTSD symptoms in people given a low dose of MDMA with therapy versus a high dose of MDMA with therapy?
Researchers will compare two sessions of MDMA-assisted therapy with either 25 mg of MDMA HCl or 125 mg of MDMA HCl in Stage 1.
Participants will undergo preparatory therapy sessions without any study drug, followed by two sessions of MDMA-assisted therapy, each followed by integrative therapy sessions without study drug. Participants who received 25 mg during Stage 1 will be given the option to enroll in Stage 2 and complete two additional open-label MDMA-assisted therapy sessions with the full dose of 125 mg MDMA.
This randomized, double-blind, active placebo-controlled Phase 2 pilot study investigated the safety and efficacy of MDMA-assisted psychotherapy in 10 people with chronic, treatment-resistant posttraumatic stress disorder (PTSD), comparing the effects of low and full dose MDMA as an adjunct to psychotherapy. The first two subjects were enrolled in the open label full dose lead-in with 125 mg of midomafetamine HCl, followed by a supplemental half-dose of 62.5 mg after 1.5 to 2.5 hours. The remaining eight subjects enrolled in Stage 1 of the study and received either an active placebo dose (low dose of 25 mg midomafetamine HCl with a supplemental half-dose of 12.5 mg) or a fully active dose (125 mg midomafetamine HCl with a supplemental half-dose of 62.5 mg) during two experimental psychotherapy session, each lasting six to eight hours and scheduled three to five weeks apart.
Upon enrollment, subjects met with their therapist team for three preparatory sessions. After each MDMA-assisted psychotherapy session, subjects met with their therapist team for integrative psychotherapy sessions.
The extent of PTSD symptoms was assessed at baseline and two months after the second experimental session using the Clinician Administered PTSD Scale (CAPS) (Blake et al., 1995). Safety measures, vital signs, and a measurement of psychological distress was assessed during all experimental sessions. Blood pressure and heart rate were assessed periodically during each experimental session.
Subjects who enrolled in Stage 1 and received the active placebo had the opportunity to enroll in Stage 2 of the study and complete open-label experimental sessions with the fully active dose of midomafetamine HCl (125 mg and 62.5 mg supplemental) on the same schedule as Stage 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive open-label MDMA with an initial dose of 125 mg midomafetamine HCl, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
Drug: Open-Label Full Dose MDMA-assisted therapy (125 mg) · Behavioral: Psychotherapy
Participants receive initial dose of 25 mg midomafetamine HCl, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
Drug: Active Placebo Dose MDMA-assisted therapy (25 mg) · Behavioral: Psychotherapy
Participants receive initial dose of 125 mg midomafetamine HCl, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
Drug: Full Dose MDMA-assisted therapy (125 mg) · Behavioral: Psychotherapy
Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl
Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl
Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl
Non-directive psychotherapy will be conducted throughout the study.
Also known as: Manualized MDMA-assisted psychotherapy
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to End of Stage 2
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to 12 months post-final experimental session
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Time frame: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Time frame: Baseline to End of Stage 2
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Time frame: Baseline to 12 month post-final experimental session
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 1
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 2
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
Time frame: Baseline to End of Stage 2
Change in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
Time frame: Baseline to 12 months post-final experimental session
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
Time frame: Baseline to End of Stage 2
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
Time frame: Baseline to 12 months post-final experimental session
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline to End of Stage 2
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline to 12 months post-final experimental session
Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, through the Israeli Defense Forces (IDF) and through word of mouth.
| Milestone | Open-Label: 125 mg MDMA-assisted Therapy | Blinded: Full Dose MDMA-assisted Therapy | Blinded: Active Placebo Dose MDMA-assisted Therapy |
|---|---|---|---|
| Started | 2 | 5 | 3 |
| Completed | 2 | 5 | 3 |
| Not completed | 0 | 0 | 0 |
| Milestone | Open-Label: 125 mg MDMA-assisted Therapy | Blinded: Full Dose MDMA-assisted Therapy | Blinded: Active Placebo Dose MDMA-assisted Therapy |
|---|---|---|---|
| Started | 0 | 0 | 2 |
| Completed | 0 | 0 | 2 |
| Not completed | 0 | 0 | 0 |
| Milestone | Open-Label: 125 mg MDMA-assisted Therapy | Blinded: Full Dose MDMA-assisted Therapy | Blinded: Active Placebo Dose MDMA-assisted Therapy |
|---|---|---|---|
| Started | 2 | 5 | 3 |
| Completed | 2 | 5 | 2 |
| Not completed | 0 | 0 | 1 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1 | -42.0 ± 9.90 | -9.0 ± 15.62 | -34.6 ± 16.29 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Stage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy |
|---|---|
| Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2 | -23.0 ± 15.56 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up | -39.0 ± 14.14 | -34.5 ± 20.51 | -48.8 ± 20.39 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1 | -17.0 ± 2.83 | 0.3 ± 4.73 | -17.0 ± 12.59 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
| score on a scale | Stage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy |
|---|---|
| Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2 | -6.5 ± 4.95 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up | -17.0 ± 5.66 | -3.5 ± 4.95 | -18.4 ± 11.10 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 1 | 15.0 ± 21.21 | -2.3 ± 8.74 | 18.2 ± 11.14 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
| score on a scale | Stage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy |
|---|---|
| Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 2 | 8.0 ± 9.90 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up | 5 ± 7.07 | -1.5 ± 0.71 | 26.6 ± 10.33 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1 | -19.0 ± 5.66 | 1.3 ± 13.43 | -17.4 ± 9.91 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
| score on a scale | Stage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy |
|---|---|
| Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2 | -11.5 ± 10.61 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up | -23.0 ± 0 | -10 ± 9.90 | -20.4 ± 12.70 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1 | -7.5 ± 6.36 | 1.0 ± 5.29 | -1.8 ± 4.44 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Stage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy |
|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2 | -3.5 ± 3.54 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up | -3.5 ± 3.54 | -2.0 ± 4.24 | -2.2 ± 5.40 |
Collected over From baseline to study completion (approximately 18 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lead In Open-Label: 125 mg MDMA-assisted Therapy | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Blinded Full Dose MDMA-assisted Therapy (125 mg) (Stage 1) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Blinded Active Placebo MDMA-assisted Therapy (Stage 1) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Open-Label Full Dose MDMA-assisted Therapy (125 mg) (Stage 2) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| 12 Month Follow-Up: Open-Label Full Dose Lead-In | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| 12 Month Follow-Up: Blinded Full Dose | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| 12 Month Follow-Up: Active Placebo Dose | 0/2 (0%) | 0/2 (0%) | 0/3 (0%) |
| SRRs: Full Dose | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| SRRs: Active Placebo | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Lead In Open-Label: 125 mg MDMA-assisted Therapy | Blinded Full Dose MDMA-assisted Therapy (125 mg) (Stage 1) | Blinded Active Placebo MDMA-assisted Therapy (Stage 1) | Open-Label Full Dose MDMA-assisted Therapy (125 mg) (Stage 2) | 12 Month Follow-Up: Open-Label Full Dose Lead-In | 12 Month Follow-Up: Blinded Full Dose | 12 Month Follow-Up: Active Placebo Dose | SRRs: Full Dose | SRRs: Active Placebo |
|---|---|---|---|---|---|---|---|---|---|
| AnxietyPsychiatric disorders | 1/2 | 4/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 5/5 | 1/3 |
| InsomniaPsychiatric disorders | 1/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 5/5 | 1/3 |
| FatigueGeneral disorders | 0/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 5/5 | 2/3 |
| HeadacheNervous system disorders | 0/2 | 1/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 4/5 | 0/3 |
| Low moodGeneral disorders | 0/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 3/5 | 2/3 |
| Muscle tensionGeneral disorders | 0/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 2/5 | 2/3 |
| RestlessnessGeneral disorders | 0/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 3/5 | 2/3 |
| Need more sleepGeneral disorders | 0/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 3/5 | 1/3 |
| PyrexiaGeneral disorders | 1/2 | 1/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 0/5 | 0/3 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/5 | 0/3 | 0/2 | 0/2 | 0/5 | 0/3 | 0/5 | 0/3 |
| Age, Continuous(years) | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Mean | 40.5 ± 19.72 | 35.1 ± 10.21 | 38.5 ± 8.68 | 37.2 ± 10.57 |
| Sex: Female, Male(Participants) | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Female | 1 | 3 | 0 | 4 |
| Male | 1 | 2 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 5 | 3 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Lead in: 125 mg MDMA (Open Label) and Psychotherapy | Full Dose MDMA (125 mg) and Psychotherapy | Active Placebo Dose MDMA (25 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Ethnicity — White/Caucasian | 2 | 5 | 2 | 9 |
| Ethnicity — Other | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2013 to primary completion in Apr 2016, 38 months.
Results were first posted in Oct 2020, 4 years 6 months after primary completion. A results delay was requested in Aug 2018.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 38 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →